Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Licorice zinc is a mineral-organic complex consisting of zinc and active components from licorice (*Glycyrrhiza uralensis*), primarily glycyrrhizic acid. Developed and manufactured as an active pharmaceutical ingredient (API) by Shaanxi Fujie Pharmaceutical, it is used as a mucosal protective agent in the treatment of gastric and duodenal ulcers. The zinc component promotes tissue repair, protein synthesis, and cell proliferation, while the licorice component provides anti-inflammatory and anti-ulcer effects by increasing gastric mucosal prostaglandin levels and inhibiting pepsin activity. It is also indicated for recurrent aphthous stomatitis (mouth ulcers) and zinc deficiency-related conditions such as pica and growth retardation in children.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on licorice zinc.